Nutex Health, Inc. (NUTX) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Outstanding 225.5% revenue growth YTD, positive net income, expanding EBITDA margins reaching 35%, strong cash flow and liquidity, combined with sustained technical momentum (+9% price gain) support NUTX as a hot idea despite ongoing legal risks requiring monitoring.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠High Leverage ⢠Margin Pressure NUTX looks financially solid on liquidity, cash generation, and valuation, but leverage, margin volatility, and minority-interest dilution temper the upside.
Price Behavior
Key Price Behavior Insights: ⢠Support Holding ⢠Resistance Capped ⢠Rebound Attempt Support Level: $128-$130 Resistance Level: $135-$136 Last month, NUTX rebounded from $118.88 and is holding $128-$130, but it remains capped by $135-$136 resistance and needs a clean breakout to confirm strength.
AI Summary
NUTX now looks less like a simple undervalued healthcare play and more like a high-risk prove-it story: solid liquidity and cash flow support the balance sheet, but HaloMD revenue scrutiny, internal-control/disclosure concerns, and margin compression mean the stock should only be considered if management can quickly validate earnings quality and legal/accounting credibility.
Description
Nutex Health, Inc. is a Houston-based, technology-enabled healthcare services company with two operating segments: a Hospital division that owns and operates 21 facilities across eight states, including micro-hospitals, specialty hospitals and hospital outpatient departments; and a Population Health Management division that manages provider networks and delivers management and administrative support to affiliated hospitals and physician groups. The population health unit also maintains a proprietary cloud platform that consolidates clinical and administrative data from multiple systems to provide a comprehensive view of patients and providers and to support care delivery.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 31 | Jan 7 | NUTX | Nutex Health, Inc. | Outstanding 225.5% revenue growth YTD, positive net income, expanding EBITDA margins reaching 35%, strong cash flow and liquidity, combined with sustained technical momentum (+9% price gain) support NUTX as a hot idea despite ongoing legal risks requiring monitoring. | Closed | +8.2% |